Department of Radiation Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241280433. doi: 10.1177/15330338241280433.
Inflammation plays an important role in the process of cancer development. The number of studies evaluating the ability of inflammatory biomarkers to predict survival has increased in recent years. This study aimed to comprehensively evaluate the predictive role of inflammatory biomarkers in patients with larynx cancer undergoing definitive radiotherapy. A total of 101 patients who underwent definitive radiotherapy for larynx cancer at our center were retrospectively examined. Blood samples were taken from the patients before radiotherapy to obtain biomarkers such as C-reactive protein (CRP), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), pan-immune inflammatory value (PIV), hemo-eosinophil inflammation index (HEI), albumin, and Lactate dehydrogenase (LDH). The study examined the predictive value of parameters for progression-free survival (PFS), local recurrence-free survival (LRFS), and overall survival (OS) using both univariate and multivariate Cox regression analysis. In the univariate analysis, the biomarkers that predicted PFS were SII, PIV, CRP, and Eastern Cooperative Oncology Group Performance Status (ECOG PS). According to the multivariate analysis, only CRP was found to be a significant predictor of PFS. In the univariate analysis, the following biomarkers were found to predict OS: NLR, PLR, MLR, SII, PIV, CRP, HEI, stage, and ECOG PS. In the multivariate analysis, NLR and ECOG PS were found to be predictors of OS. A significant difference was found in MLR, PIV, and CRP values based on the presence of lymphatic metastasis. The current study is the first to comprehensively examine the relationship between larynx cancer and several inflammatory biomarkers. Many of these biomarkers have been shown to predict both PFS and OS in patients with larynx cancer undergoing definitive radiotherapy. It has been shown that PIV and CRP may predict the presence of lymphatic metastases in addition to PFS and OS.
炎症在癌症发展过程中起着重要作用。近年来，评估炎症生物标志物预测生存能力的研究数量有所增加。本研究旨在全面评估炎症生物标志物在接受根治性放疗的喉癌患者中的预测作用。回顾性分析了我院 101 例行根治性放疗的喉癌患者。放疗前采集患者血样，获得 C 反应蛋白（CRP）、中性粒细胞-淋巴细胞比值（NLR）、血小板-淋巴细胞比值（PLR）、单核细胞-淋巴细胞比值（MLR）、全身性免疫炎症指数（SII）、全免疫炎症值（PIV）、嗜酸性粒细胞炎症指数（HEI）、白蛋白和乳酸脱氢酶（LDH）等生物标志物。采用单因素和多因素 Cox 回归分析，研究了各参数对无进展生存期（PFS）、局部无复发生存期（LRFS）和总生存期（OS）的预测价值。单因素分析中，SII、PIV、CRP 和东部合作肿瘤学组体能状态（ECOG PS）是预测 PFS 的生物标志物。多因素分析发现，仅 CRP 是 PFS 的显著预测因子。单因素分析中，NLR、PLR、MLR、SII、PIV、CRP、HEI、分期和 ECOG PS 是预测 OS 的生物标志物。多因素分析发现，NLR 和 ECOG PS 是 OS 的预测因子。根据有无淋巴转移，MLR、PIV 和 CRP 值存在显著差异。本研究首次全面探讨了喉癌与多种炎症生物标志物的关系。多项研究表明，这些生物标志物均能预测接受根治性放疗的喉癌患者的 PFS 和 OS。研究表明，PIV 和 CRP 除了预测 PFS 和 OS 外，还可能预测淋巴转移的存在。
